The question is what role will MABs play in treatment of solid cancers. We've gone from the unrealistic hope/expectation of a cure with an MAB to using one or more of them as adjunctive therapy with chemo, irradiation, and surgery, a strategy which makes sense. As usual with scientific inquiry, the spinoffs may be as valuable as the intended use. In the case of Bavi, it actually seems to make sense to use it for tumor treatment imaging,to monitor tumorcidal effects of various drugs on various solid cancers. That includes both prospective medications in the developmental pipeline, AND established medications. It is one thing to do genetic tumor typing, but the proof is in the pudding when it comes to whether or not medication actually kills cancer, and Bavi has the ability to dial that in. Do I think Roche is controlling events here? I've thought that for several years, and no event during that time has altered that opinion. The most puzzling thing about PPHM at this point is if the market is a gamble, nobody seems to be taking the bet, and that is a bit scary VERY strange in my experience. I just do not see how the company can defer truly important results for weeks in deference to the rules of a meeting such as the upcoming clinical oncology confab. We've been down that road too many times. To come out on this stock you have to be dollar cost averaging in at regular intervals, and I am simply too exhausted with it all, and broke, to keep doing it. This is a very convoluted way of saying I am still hoping...and holding...
